Neurocrine Biosciences, Inc.
DE ˙ DB ˙ US64125C1099
134,65 € ↑0,30 (0,22%)
2026-06-03
AKTIENPREIS
SecurityDE:NB3 / Neurocrine Biosciences, Inc.
InstitutionEmpowered Funds, LLC
Latest Disclosed Ownership83,971 shares
Latest Disclosed Value $ 11,062,339
Empowered Funds, LLC ownership in NB3 / Neurocrine Biosciences, Inc.

On May 15, 2026 - Empowered Funds, LLC filed a 13F-HR form disclosing ownership of 83,971 shares of Neurocrine Biosciences, Inc. (DE:NB3) valued at $9,383,759 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on February 18, 2026 disclosing 4,366 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 1,823.29% during the quarter. The current value of the position is $11,306,695 USD.

Empowered Funds, LLC has a history of taking positions in derivatives of the underlying security (NB3) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:NB3 / Neurocrine Biosciences, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 83,971 79,605 1,823.29 11,062 1,687.08 0.0309
2026-02-18 2025-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 4,366 -14,458 -76.81 619 -76.57 0.0105
2026-02-11 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,366 -14,458 619 0.0049
2025-11-13 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,824 8,135 76.11 2,643 96.72 0.0267
2025-08-11 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,689 -1,366 -11.33 1,344 0.75 0.0152
2025-05-16 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,055 12,055 1,333 0.0190
2025-01-28 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -62,052 -100.00 0 -100.00
2024-11-06 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 62,052 54,114 681.71 7,150 554.67 0.1124
2024-07-30 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,938 111 1.42 1,093 1.20 0.0189
2024-05-07 2024-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 7,827 -13,211 -62.80 1,080 -61.06 0.0195
2024-05-06 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,827 -13,211 1,080 0.0093
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 21,038 -16,622 -44.14 2,772 -34.58 0.0696
2023-11-01 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 37,660 20,651 121.41 4,237 164.25 0.1249
2023-07-27 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 17,009 8,636 103.14 1,604 89.26 0.0564
2023-04-05 2023-03-31 13F NEMAURA MED CALL 64125C109 0 -13,386 -100.00 0 -100.00
2023-04-05 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,373 -5,013 -37.45 848 -47.00 0.0500
2023-02-21 2022-12-31 13F/A-1 NEMAURA MED CALL 64125C109 13,386 13,386 1,599 0.1045
2023-01-26 2022-12-31 13F NEMAURA MED CALL 64125C109 13,386 13,386 2 0.1044
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2023-04-05 2023-03-31 13F NEMAURA MED CALL 0 -100.00 0 -100.00 n/a n/a n/a
2023-02-21 2022-12-31 13F/A NEMAURA MED CALL 13,386 1,599 n/a n/a n/a
2023-01-26 2022-12-31 13F NEMAURA MED CALL 13,386 2 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.